Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RUA Life SciencesLSE:RUA +4.35%47 Net Margin % is -7.32% as of Mar. 2026. GuruFocus rates LSE:RUA with a GF Score™ of 47/100 and a GF Value™ of £0.17 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 817 Medical Devices & Instruments companies, RUA Life Sciences ranks worse than 62.06% on this metric.
The historical rank and industry rank for RUA Life Sciences's Net Margin % or its related term are showing as below:
LSE:RUA'
s Net Margin % Range Over the Past 10 Years
Min: -166.87 Med: -86.12 Max: -7.32
Current: -7.32
LSE:RUA's Net Margin % is ranked worse than 62.06% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.13
vs LSE:RUA: -7.32
RUA Life Sciences (LSE:RUA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
RUA Life Sciences Net Margin % Related Terms
RUA Life Sciences Net Margin % Historical Data
* Premium members only.
The historical data trend for RUA Life Sciences's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, RUA Life Sciences's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RUA Life Sciences Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, RUA Life Sciences's Net Margin % distribution charts can be found below:
* The bar in red indicates where RUA Life Sciences's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RUA Life Sciences (LSE:RUA) has a Net Margin % of -7.32% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on RUA Life Sciences and its competitors. According to the industry distribution chart, RUA Life Sciences ranks #507 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 62.1%.
Is RUA Life Sciences' Net Margin % too high?
RUA Life Sciences' current Net Margin % is -7.32%. Based on the distribution chart, RUA Life Sciences ranks #507 out of 817 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, RUA Life Sciences has a GF Score™ of 47/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does RUA Life Sciences' Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, RUA Life Sciences ranks #507 out of 817 companies for Net Margin %. This places RUA Life Sciences in the lower half of its industry. The industry median Net Margin % is 2.13. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.13, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on RUA Life Sciences and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RUA Life Sciences's current Net Margin % is -7.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RUA Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, RUA Life Sciences (LSE:RUA) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.17, compared to a current price of £0.24 — trading 41.2% above its estimated fair value. The current Net Margin % is -7.32%. RUA Life Sciences' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For RUA Life Sciences (LSE:RUA), the current Net Margin % is -7.32% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RUA Life Sciences (LSE:RUA) Overvalued in 2026?
Based on GuruFocus' analysis, RUA Life Sciences stock appears to be overvalued.
The current stock price of £0.24 is trading 41.2% above its estimated GF Value™ of £0.17.
GuruFocus considers RUA Life Sciences to be Significantly Overvalued.
Key valuation signals for LSE:RUA:
Net Margin %: -7.32%
GF Value™: £0.17 vs. price of £0.24 (41.2% above fair value)
No single metric tells the full story. See the LSE:RUA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RUA Life Sciences PLC is engaged in the contract design and manufacture of medical devices, exploiting the value of its IP and know-how, and developing cardiovascular devices. The Biomaterials segment is a licensor of Elast-Eon polymers to the medical device industry. The Medical Devices & Components segment is an end-to-end contract developer and manufacturer of medical devices and an implantable fabric specialist, which generates maximum revenue. The Vascular segment focuses on the development and commercialisation of the Group's Elast-Eon sealed Vascular Graft products. The Structural Heart segment focuses on the development of the Group's tri-leaflet polymeric heart valves. Geographically, it operates in Europe, North America, Middle East, Asia Pacific, and Africa.
47GF Score
Get the complete analysis for LSE:RUA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:RUA has been successfully added to your 
